Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.Cancer Letters.  436:75-86. 2018
2017 JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma.Molecular Cancer Therapeutics.  17:107-118. 2017
2017 DNA topoisomerase-targeting chemotherapeutics: what's new?Cancer Chemotherapy and Pharmacology.  80:1-14. 2017
2016 Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin.Oncotarget.  7:86660-86674. 2016
2016 Tyrosyl-DNA Phosphodiesterase I a critical survival factor for neuronal development and homeostasis.J Neurol Neuromedicine.  1:25-29. 2016
2015 ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin.Oncogene.  34:1553-1562. 2015
2015 Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavage.Journal of Biological Chemistry.  290:6203-6214. 2015
2014 Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target.Drug Metabolism Reviews.  46:494-507. 2014
2012 Erratum: Analysis of the active-site mechanism of tyrosyl-DNA phosphodiesterase I: A member of the phospholipase D superfamily (Journal of Molecular Biology (2012) 415:4 (741-758))Journal of Molecular Biology.  416:725. 2012
2012 Analysis of the active-site mechanism of tyrosyl-DNA phosphodiesterase I: a member of the phospholipase D superfamily.Journal of Molecular Biology.  415:741-758. 2012
2007 Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison.Journal of Molecular Biology.  372:1070-1081. 2007
2007 Structure of a SUMO-binding-motif mimic bound to Smt3p-Ubc9p: conservation of a non-covalent ubiquitin-like protein-E2 complex as a platform for selective interactions within a SUMO pathway.Journal of Molecular Biology.  369:619-630. 2007
2006 Distinct functional domains of Ubc9 dictate cell survival and resistance to genotoxic stress.Molecular and Cellular Biology.  26:4958-4969. 2006
2005 Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage.Journal of Biological Chemistry.  280:23566-23575. 2005
2004 Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.Journal of Biological Chemistry.  279:54502-54509. 2004
2004 Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.Cancer Chemotherapy and Pharmacology.  54:71-78. 2004
2004 Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons.Molecular Cancer Therapeutics.  3:393-402. 2004
2003 In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.Anti-Cancer Drugs.  14:405-410. 2003
2003 DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.Biochemical Pharmacology.  65:275-282. 2003
2002 DNA-based drug interactions of cisplatin.Cancer Treatment Reviews.  28:291-303. 2002
2002 Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.Anti-Cancer Drugs.  13:87-91. 2002
2001 Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.Clinical Cancer Research.  7:935-941. 2001
1999 32P-postlabeling assay for the quantification of the major platinum-DNA adducts.Analytical Biochemistry.  275:30-38. 1999
1999 Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.Cancer Research.  59:4559-4563. 1999
1998 Effects of c-MYC oncogene modulation on differentiation of human small cell lung carcinoma cell linesAnticancer Research.  18:91-95. 1998
1998 Effects of c-myc oncogene modulation on differentiation of human small cell lung carcinoma cell lines.Anticancer Research.  18:91-95. 1998
1997 Effects of an inducible anti-sense c-myc gene transfer in a drug- resistant human small-cell-lung-carcinoma cell lineInternational Journal of Cancer.  73:544-550. 1997
1997 Effects of an inducible anti-sense c-myc gene transfer in a drug-resistant human small-cell-lung-carcinoma cell line.International Journal of Cancer.  73:544-550. 1997
1996 Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell linesAnticancer Research.  16:1963-1970. 1996
1996 Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines.Anticancer Research.  16:1963-1970. 1996

Chapter

Year Title Altmetric
2015 The ubiquitin/proteasome pathway in neoplasia.  473-480. 2015

Education And Training

  • Doctorate Level Degree in Oncology and Cancer Biology, University of Groningen
  • Full Name

  • Robert van Waardenburg
  • Blazerid

  • rvanwaar